p rimary end point (cv death, mi and stroke at 15 months)

TRITON TIMI-38 STEMI cohort

Primary End Point (CV death, MI and stroke at 15 months)

Adapted from Montalescot et al. ESC 2008.

Time (days)

5

10

15

00 50 100 150 200 250 300 350 400 450

Pro

po

rtio

n o

f p

atie

nts

(%

)

9.5

6.5

12.4

10.0

HR=0.79 (0.65–0.97) NNT=42

P=0.02RRR=21%

P=0.002RRR=32%

Clopidogrel

Prasugrel

Age-adjusted HR=0.81 (0.66-0.99)


Efficacy End Points at 15 Months

Clopidogrel

Prasugrel

0

2

4

6

8

10

12

14

P=0.11

P=0.02

P=0.09P=0.02

P=0.007 P=0.03 P=0.02

Pro

po

rtio

n o

f p

op

ula

tio

n (

%)

All Death MI UTVR StentThrombosis*

CV Death/MI

CV Death/MI/UTVR

CV Death/MI/Stroke

* ARC def/probable



Stent thrombosis ARC Definite/probable

HR=0.58 (0.36–0.93) NNT=83

P=0.02 RRR=42%

0 100 200 300 4000

1

2

3

Pro

po

rtio

n o

f p

atie

nts

(%

)

Time (Days)

2.4

1.2

2.8

1.6P=0.008RRR=51%

Clopidogrel

Prasugrel




TIMI major non-CABG bleeding

0.5

1.0

2.0

2.5

1.5

2.1

2.4

HR=1.11 (0.70–1.77) NNH=333Pro

po

rtio

n o

f p

atie

nts

(%

)

Time (Days)

P=0.65

0 100 200 300 4000

ClopidogrelPrasugrel




End point Nondiabetics, HR (95% CI)

Diabetics, HR (95% CI)

P for interaction

CV death, nonfatal MI, or stroke*

0.86(0.76–0.98)

0.70(0.58–0.85)

0.09

MI 0.82(0.72–0.95)

0.60(0.48–0.76)

0.02

Major hemorrhage 1.43(1.07–1.91)

1.06(0.66–1.69)

0.29

Major or minor hemorrhage

1.32(1.08–1.61)

1.30(0.92–1.82)

0.93

All-cause death or nonfatal MI, stroke, or major hemorrhage

0.92(0.82–1.03)

0.74(0.62–0.89)

0.05

Adapted from Wiviott et al. Circulation 2008; available at: http://circ.ahajournals.org.

*primary end point

Hazard Ratios for Primary and Other End Points, Prasugrel vs. Clopidogrel, for Nondiabetics and Diabetics in TRITON-TIMI 38

p rimary end point (cv death, mi and stroke at 15 months)

Documents